medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 6

<< Back Next >>

Gac Med Mex 2003; 139 (6)

The Metabolic Syndrome in Postmenopausal Women. Clinical Implications

Zárate A, Basurto L, Hernández M

Language: Spanish
References: 18
Page: 625-628
PDF size: 77.86 Kb.


ABSTRACT

Cardiovascular diseases (CVD) remain the major cause of death in postmenopausal women. Before menopause, women are relatively protected from ischemic heart disease and thromboemolism by their circulating estrogens, but this protection is lost after menopause. Following menopause, adverse lipid changes occur and the levels of several coagulation factor increase. One of the major predisposing factors for CVD is the metabolic syndrome, including myriad risk biomarkers: abdominal girth, blood pressure, fasting glucose, triglycerides, lipids. In many ways, the metabolic syndrome is a precursor to the development of abnormalities of insulin action and diabetes. In parallel, there are effects upon blood coagulation and fibrinolysis. Common preventive therapies require rigorous evaluation. Hormone replacement therapy (HRT) has not produced the expected reduction in CVD and the ideal HRT is probably unobtainable. For long-term HRT users, the risk of thromboembolism needs to be weighed against probable benefits. With respect to the effects of HRT, oral estrogen is associated with elevation in C-reactive protein and varied effects on IL-6, but transdermal estradiol has no significant effect on these parameters. Despite the varied effects of HRT on inflammatory biomarkers, there is no definitive evidence that change in these markers results in modification of cardiovascular risk.


REFERENCES

  1. Knopp RH. Risk factors for coronary artery disease in women. Am J Cardiol 2002;89:28E-35E.

  2. Zárate A, Fonseca E, Ochoa R, Basurto L, Hernandez-Valencia M. Low-dose conjugated equine estrogens elevate circulating neurotransmitters and improve the psychological well-being of menopausal women. Fertil Steril 2002;77:952-955.

  3. Fonseca E, Ochoa R, Galván R, Hernández-Valencia M, Mercado M, Zárate A. Increased serum leveis of growth hormone and insufin-iike growth factor-1 associated with simultaneous decrease of circulating insulin in postmenopausal women receiving hormone replacement therapy. Menopause 1999;6:56-60.

  4. Criqui MH, Langer RD, Fronek A. Mortaiity over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386.

  5. Phillips GB, PinkerneW BH, Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscier Thromb Vasc Biol1997;17:695-701.

  6. Groop L, Orho-Melander M. The dysmetabolic syndrome. J lntern Med 2001;250:105-120.

  7. Wamala SP, Lynch J, Horsten MMA, Mittieman MA, Schenck-Gustafsson K, Orth-Gomer K. Education and the metabolic syndrome in women. Diabetes Care 2000;22:1999-2003.

  8. Sakkinen PA, Wahi P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000;152:897-907.

  9. Lupattelli G, Pascualini L, Siepi D, Marchesl S, Pirro M, Vaudo G, Ciuffetti G, Mannarino E. lncreased postprandial lipemia in patients with normolipemic peripheral arterial disease. Am Heart J 2002;143:733-738.

  10. Harris TB, Ferruci L, Tracy RP, Corti MC, Wacholer S, Ettinger WH, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein leveis with mortality in the elderly. Am J Med 1999;106:506-512.

  11. Orth-Gomer K, Mittieman MA, Shenck-Gustafsson K, Wamala SP, Erickson M, Belkic K, Kirkeeide R, Svane B, Ryden L. Lipoprotein (a) as a determinant of coronary heart disease in younger women. Circulation 1997-195:329-334.

  12. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-2478.

  13. Zárate A, Basurto L, Hernández-Valencia M. Los trastornos tiroideos en la mujer. Ginecol Obstet Mex 2001;69:200-205.

  14. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:835-843.

  15. Lasco A, Alvaro S, Frisina N, Di Benedetto A, Denuzzo G, Cucinotta D. Longterm transdermal estrogen therapy improves lipid profile not insulin resistance in healthy postmenopausal women. Diabetes Care 2000; 23:422-424.

  16. Sacks FM, Pfeiffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol leveis. N Engi J Med 1996;335:1001-1009.

  17. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-578.

  18. Shapiro M. Menopause: current controversias in hormone replacement Geriatrics & Aging 2003;6:30-33.




2020     |     www.medigraphic.com